PMGC Holdings Inc., doing business as NorthStrive Holdings, Inc, a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.…
NorthStrive Defense Tech Announces Successful Completion of Technical Validation and Update to Acquire GPS-Denied Drone Navigation Technology
PMGC Holdings (NASDAQ: ELAB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 32 employees.
The shares were at 1.140 USD on 20 November 2026, down 99.9% over 52 weeks. Its 52-week range is 1.140 USD to 1471.20 USD, and it trades at the bottom of that range.
Its market capitalisation is 1.33M USD.
PMGC Holdings reports return on equity of -98.9% and an operating margin of -470.0%.
It holds more cash than debt, a net cash position of 4.73M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.